---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088956"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:49:37.563145+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alumis Q2 net loss $56.5M, cash $209.5M; Phase 3 psoriasis trial initiated

## Summary
- Net loss $56.5M for Q2 2024 vs $36.3M in Q2 2023; R&D expense $48.6M (up from $32.8M).
- Cash and marketable securities $209.5M at June 30; IPO net proceeds $233.2M extend runway into 2026.
- Initiated ESK-001 Phase 3 ONWARD program in moderate-to-severe plaque psoriasis; topline expected 2026.
- Completed IPO and concurrent private placement raising $250M gross proceeds (15.625M shares at $16.00).
- Phase 1 trial for A-005 (CNS-penetrant TYK2 inhibitor) dosed first healthy volunteer in April 2024.

## SEC filing metadata
- accession: 0001104659-24-088956
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465924088956/0001104659-24-088956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465924088956/tm2421483d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088956
- JSON: https://secwatch.observer/filing/0001104659-24-088956.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.